KalVista Pharmaceuticals, Inc. (KALV)
26.76
0.00 (0.00%)
USD |
NASDAQ |
May 19, 14:54
KalVista Pharmaceuticals Research and Development Expense (Quarterly) : 12.42M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 78.54M |
| Recursion Pharmaceuticals, Inc. | 75.20M |
| Sensei Biotherapeutics, Inc. | 2.536M |
| Tango Therapeutics, Inc. | 33.07M |
| BioCryst Pharmaceuticals, Inc. | 59.26M |